The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study

BACKGROUND: Although immune checkpoint inhibitor (ICI) monotherapy remains the standard of second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) , the objective response rate (ORR) is low. There is an urgent need to increase the response population of second-line immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bolin, Wang, Jingyi, Pu, Xingxiang, Li, Jia, Wang, Qianzhi, Liu, Liyu, Xu, Yan, Xu, Li, Kong, Yi, Li, Kang, Xu, Fang, Liang, Shuzhi, Cardona, Andrés F., Wu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641046/
https://www.ncbi.nlm.nih.gov/pubmed/36386462
http://dx.doi.org/10.21037/tlcr-22-697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641046/
https://www.ncbi.nlm.nih.gov/pubmed/36386462
http://dx.doi.org/10.21037/tlcr-22-697

Ejemplares similares